Male Aesthetics Market by Treatment Type (Minimally Invasive Procedures, Non-Invasive Procedures, Surgical Procedures), Technology (Laser Technology, Radiofrequency, Ultrasound), Provider Type, Treatment Frequency, Outcome Duration - Global Forecast 2025-
Description
The Male Aesthetics Market was valued at USD 6.17 billion in 2024 and is projected to grow to USD 6.61 billion in 2025, with a CAGR of 7.71%, reaching USD 11.17 billion by 2032.
An incisive introduction to how consumer normalization, clinical innovation, and provider evolution are reshaping demand and strategic priorities in male aesthetics
The male aesthetics landscape is undergoing a pronounced maturation as consumer attitudes, clinical practice, and device innovation converge to create new opportunities and strategic complexity. Men are increasingly framing aesthetic treatments as elements of routine health and personal grooming rather than episodic or stigmatized interventions, and this shift is reshaping demand profiles, referral pathways, and provider positioning. As a result, stakeholders from device makers to clinic owners must rethink product messaging, service design, and patient journeys to meet evolving expectations.
In parallel, technology advances are expanding the palette of safe, office-based options that reduce downtime and lower the barrier to trial. This technological diversification, together with a more informed consumer base and broader insurance and regulatory dialogue, requires firms to move beyond traditional segmentation and to integrate clinical efficacy with consumer experience design. Consequently, strategic leaders need clear frameworks for prioritizing investments, forming partnerships, and aligning go-to-market plans with the nuanced preferences of male patients.
A clear-eyed synthesis of the key transformative shifts in consumer behavior, procedural hybridity, and clinical access that are altering the male aesthetics competitive environment
Several transformative shifts are redefining competitive advantage across the male aesthetics arena, and they are interdependent rather than isolated. First, the destigmatization of aesthetic care for men has broadened the addressable audience and diversified motivations from purely cosmetic to maintenance, performance, and age management. This evolution has encouraged nontraditional entry points into care, such as grooming-adjacent clinics and franchised chains that translate retail convenience into clinical access.
Second, the technical landscape is moving toward hybridized treatment pathways that combine minimally invasive and non-invasive modalities to optimize outcomes while minimizing recovery. These combinations are supported by incremental improvements in laser, radiofrequency, and ultrasound platforms that increase precision and patient comfort. Third, shifting reimbursement dialogues and supply-chain realities are prompting providers to seek predictable, repeatable procedures with clear outcome durations, which in turn affects investment decisions for devices and consumables. Taken together, these shifts mandate a strategic response that balances clinical credibility, consumer-facing convenience, and operational scalability.
Strategic implications of 2025 tariff developments on sourcing agility, nearshoring trends, and procurement discipline across device manufacturers and provider networks
The cumulative implications of recent tariff policies and trade dynamics in 2025 are reshaping sourcing, manufacturing, and pricing strategies across the value chain. Manufacturers dependent on cross-border components are recalibrating supplier relationships to preserve margin and ensure continuity of device availability. In response, some firms are accelerating nearshoring and diversifying component sourcing to mitigate single-source exposure, while contract manufacturers reassess capacity commitments and lead-time guarantees.
For clinical operators and purchasers, these upstream cost pressures have translated into renewed focus on procurement practices, product lifecycle management, and clinical prioritization of durable or consumable-light modalities. Moreover, the tariff environment has catalyzed dialogue between commercial leaders and regulatory teams to clarify classification and compliance that could affect customs treatment. Ultimately, the policy changes in 2025 emphasize the need for scenario planning that spans procurement, pricing architecture, and strategic relationships with technology partners to sustain service delivery and competitive positioning.
Comprehensive segmentation analysis revealing how treatment taxonomy, technology modalities, provider models, frequency, and outcome duration combine to shape strategy and operations
A nuanced approach to segmentation exposes where growth vectors and margin pressures coexist, and the treatment taxonomy offers the most immediate operational levers. Based on Treatment Type, the market separates into Minimally Invasive Procedures - which include fat transfer, laser-assisted lipolysis, liposuction, and thread lifts - Non-Invasive Procedures - encompassing body contouring, botox injectables, hair removal, hair restoration (non-surgical), pigment and scar correction, skin resurfacing, and skin tightening - Surgical Procedures - covering body and facial surgery plus hair transplant - and Topicals & At-Home solutions that span at-home devices and skincare. Each subcategory shapes clinical workflow, capital intensity, and patient journey design differently.
Complementing treatment-based segmentation, technology stratification across laser technology, radiofrequency, and ultrasound reveals which modalities support repeatable, low-downtime protocols and which require higher-capital investment and specialist training. Provider Type segmentation differentiates delivery models such as barbershop-adjacent grooming clinics, dermatology clinics, franchised chains, and medical spas, each with distinct regulatory, staffing, and consumer-experience implications. Treatment Frequency distinctions between maintenance/booster, one-time interventions, and series-based regimens directly influence lifetime revenue models and patient retention strategies. Finally, Outcome Duration segmentation into long-lasting, permanent, semi-permanent, and temporary outcomes informs clinical positioning, pricing premium, and marketing claims. Synthesizing these dimensions allows leaders to prioritize product development, channel strategy, and operational investments according to realistic clinical pathways and patient expectations.
Focused regional read on how Americas, Europe Middle East & Africa, and Asia-Pacific trends diverge in adoption, regulation, and commercial strategy for male aesthetics
Regional dynamics exert a profound influence on technology adoption curves, regulatory priorities, and consumer preferences, making geographic strategy a core part of executive planning. In the Americas, demand patterns emphasize convenience, hybrid service delivery, and a growing acceptance of male-targeted aesthetic packages that blend grooming with clinical care; payment models and clinic franchising continue to evolve in response. Meanwhile, Europe, Middle East & Africa features heterogeneous regulatory environments and established dermatology networks that privilege clinical evidence and specialist referrals, creating differentiated pathways for device adoption and training programs.
In Asia-Pacific, rapid consumer adoption, urbanization, and strong beauty culture drive vigorous interest in both non-invasive and at-home solutions, while manufacturing ecosystems support local device innovation and competitive pricing. These regional distinctions necessitate tailored product positioning, regulatory strategy, and channel partnerships. Cross-border expansion should therefore be staged with attention to local reimbursement nuances, training and certification expectations, and culturally informed marketing that resonates with male consumers in each region.
Key corporate strategies and competitive positioning insights highlighting how evidence, clinician education, and partnership models determine market leadership
Competitive dynamics are being reshaped by firms that combine clinical credibility with scalable commercial models, and the vendor landscape now includes specialized device manufacturers, legacy surgical brands, and nimble entrants focused on at-home modalities. Leading companies are differentiating through evidence generation, clinician education programs, and integrated service models that reduce friction for adoption. In particular, those that invest in robust clinical training and clear outcome measurement frameworks earn faster clinician trust and wider referral corridors.
At the same time, strategic partnerships between technology providers and provider networks are emerging as a preferred route to scale, enabling manufacturers to bundle hardware, consumables, and training into predictable deployment packages. Distribution partners and franchised chains that can standardize protocols and deliver consistent patient experiences gain an advantage in consumer-facing markets. Overall, market leaders will be those that align product development with clinician workflows, substantiate claims through real-world data, and create repeatable commercial models that lower the cost and complexity of adoption for provider partners.
Actionable and prioritized recommendations for executives to align product development, supply-chain resilience, and channel strategies to capture male aesthetics demand
Industry leaders should prioritize a three-part agenda that aligns product, channel, and clinical adoption to capture emergent demand and protect margins. First, accelerate investments in clinician-facing education and outcome tracking to shorten the adoption curve for higher-efficacy modalities and to justify premium pricing. These efforts should be coupled with clear protocols that reduce variability in results and create reproducible case studies for payers and referrers.
Second, diversify supply-chain footprints and pursue nearshoring or multi-sourcing where feasible to mitigate tariff exposure and improve lead-time resilience. Operationally, this also includes redesigning procurement contracts to provide flexibility in component sourcing and to lock in service-level guarantees. Third, tailor go-to-market approaches by aligning provider type strategies with treatment frequency and outcome duration profiles; for example, emphasize series-based protocols and semi-permanent outcomes in clinic channels that excel at patient retention, while promoting at-home devices and topical systems in high-frequency, convenience-driven environments. Implementing these recommendations will require cross-functional coordination among R&D, commercial, and operations teams to translate strategic intent into measurable execution.
Transparent mixed-method research methodology combining clinician interviews, device technology review, supplier validation, and scenario mapping to inform practical strategic insights
The research underpinning this analysis combined qualitative interviews with clinicians, technology executives, and provider operators alongside systematic review of regulatory filings, clinical trial registries, and publicly available product literature to triangulate trend signals. Primary engagement included structured conversations with practitioners across dermatology clinics, medical spas, franchised chains, and grooming-adjacent operators to understand clinical pathways, training requirements, and patient acceptance criteria. Secondary analysis synthesized device technology roadmaps across laser, radiofrequency, and ultrasound modalities to identify patterns in capital intensity and clinical workflow integration.
Data integrity was supported by cross-validation of supplier and distributor interviews to assess procurement dynamics and lead-time variability, and by scenario mapping to evaluate the operational impact of tariff changes. Throughout, emphasis was placed on evidence quality, reproducibility of clinical outcomes, and the practical implications for provider adoption and commercial deployment. This mixed-method approach ensured that insights are actionable and grounded in both practitioner experience and documented device performance.
Concise concluding synthesis that connects clinical credibility, operational resilience, and regional strategy into a cohesive roadmap for sustained leadership in male aesthetics
In conclusion, male aesthetics is entering a period of sustained structural change driven by shifting consumer norms, modality convergence, and supply-chain realignment. These forces create both opportunities and challenges for companies seeking to scale responsibly while maintaining clinical credibility and financial discipline. The convergence of minimally invasive and non-invasive modalities, coupled with diversified provider channels, requires an integrated approach that aligns clinical evidence, training, and repeatable patient journeys.
Moving forward, organizations that proactively address procurement resilience, invest in outcome-driven clinician engagement, and tailor regional strategies will be best positioned to capture durable value. The insights in this report are intended to inform both near-term operational decisions and longer-term portfolio planning, enabling leaders to convert trend awareness into competitive advantage without sacrificing clinical standards or patient trust.
Please Note: PDF & Excel + Online Access - 1 Year
An incisive introduction to how consumer normalization, clinical innovation, and provider evolution are reshaping demand and strategic priorities in male aesthetics
The male aesthetics landscape is undergoing a pronounced maturation as consumer attitudes, clinical practice, and device innovation converge to create new opportunities and strategic complexity. Men are increasingly framing aesthetic treatments as elements of routine health and personal grooming rather than episodic or stigmatized interventions, and this shift is reshaping demand profiles, referral pathways, and provider positioning. As a result, stakeholders from device makers to clinic owners must rethink product messaging, service design, and patient journeys to meet evolving expectations.
In parallel, technology advances are expanding the palette of safe, office-based options that reduce downtime and lower the barrier to trial. This technological diversification, together with a more informed consumer base and broader insurance and regulatory dialogue, requires firms to move beyond traditional segmentation and to integrate clinical efficacy with consumer experience design. Consequently, strategic leaders need clear frameworks for prioritizing investments, forming partnerships, and aligning go-to-market plans with the nuanced preferences of male patients.
A clear-eyed synthesis of the key transformative shifts in consumer behavior, procedural hybridity, and clinical access that are altering the male aesthetics competitive environment
Several transformative shifts are redefining competitive advantage across the male aesthetics arena, and they are interdependent rather than isolated. First, the destigmatization of aesthetic care for men has broadened the addressable audience and diversified motivations from purely cosmetic to maintenance, performance, and age management. This evolution has encouraged nontraditional entry points into care, such as grooming-adjacent clinics and franchised chains that translate retail convenience into clinical access.
Second, the technical landscape is moving toward hybridized treatment pathways that combine minimally invasive and non-invasive modalities to optimize outcomes while minimizing recovery. These combinations are supported by incremental improvements in laser, radiofrequency, and ultrasound platforms that increase precision and patient comfort. Third, shifting reimbursement dialogues and supply-chain realities are prompting providers to seek predictable, repeatable procedures with clear outcome durations, which in turn affects investment decisions for devices and consumables. Taken together, these shifts mandate a strategic response that balances clinical credibility, consumer-facing convenience, and operational scalability.
Strategic implications of 2025 tariff developments on sourcing agility, nearshoring trends, and procurement discipline across device manufacturers and provider networks
The cumulative implications of recent tariff policies and trade dynamics in 2025 are reshaping sourcing, manufacturing, and pricing strategies across the value chain. Manufacturers dependent on cross-border components are recalibrating supplier relationships to preserve margin and ensure continuity of device availability. In response, some firms are accelerating nearshoring and diversifying component sourcing to mitigate single-source exposure, while contract manufacturers reassess capacity commitments and lead-time guarantees.
For clinical operators and purchasers, these upstream cost pressures have translated into renewed focus on procurement practices, product lifecycle management, and clinical prioritization of durable or consumable-light modalities. Moreover, the tariff environment has catalyzed dialogue between commercial leaders and regulatory teams to clarify classification and compliance that could affect customs treatment. Ultimately, the policy changes in 2025 emphasize the need for scenario planning that spans procurement, pricing architecture, and strategic relationships with technology partners to sustain service delivery and competitive positioning.
Comprehensive segmentation analysis revealing how treatment taxonomy, technology modalities, provider models, frequency, and outcome duration combine to shape strategy and operations
A nuanced approach to segmentation exposes where growth vectors and margin pressures coexist, and the treatment taxonomy offers the most immediate operational levers. Based on Treatment Type, the market separates into Minimally Invasive Procedures - which include fat transfer, laser-assisted lipolysis, liposuction, and thread lifts - Non-Invasive Procedures - encompassing body contouring, botox injectables, hair removal, hair restoration (non-surgical), pigment and scar correction, skin resurfacing, and skin tightening - Surgical Procedures - covering body and facial surgery plus hair transplant - and Topicals & At-Home solutions that span at-home devices and skincare. Each subcategory shapes clinical workflow, capital intensity, and patient journey design differently.
Complementing treatment-based segmentation, technology stratification across laser technology, radiofrequency, and ultrasound reveals which modalities support repeatable, low-downtime protocols and which require higher-capital investment and specialist training. Provider Type segmentation differentiates delivery models such as barbershop-adjacent grooming clinics, dermatology clinics, franchised chains, and medical spas, each with distinct regulatory, staffing, and consumer-experience implications. Treatment Frequency distinctions between maintenance/booster, one-time interventions, and series-based regimens directly influence lifetime revenue models and patient retention strategies. Finally, Outcome Duration segmentation into long-lasting, permanent, semi-permanent, and temporary outcomes informs clinical positioning, pricing premium, and marketing claims. Synthesizing these dimensions allows leaders to prioritize product development, channel strategy, and operational investments according to realistic clinical pathways and patient expectations.
Focused regional read on how Americas, Europe Middle East & Africa, and Asia-Pacific trends diverge in adoption, regulation, and commercial strategy for male aesthetics
Regional dynamics exert a profound influence on technology adoption curves, regulatory priorities, and consumer preferences, making geographic strategy a core part of executive planning. In the Americas, demand patterns emphasize convenience, hybrid service delivery, and a growing acceptance of male-targeted aesthetic packages that blend grooming with clinical care; payment models and clinic franchising continue to evolve in response. Meanwhile, Europe, Middle East & Africa features heterogeneous regulatory environments and established dermatology networks that privilege clinical evidence and specialist referrals, creating differentiated pathways for device adoption and training programs.
In Asia-Pacific, rapid consumer adoption, urbanization, and strong beauty culture drive vigorous interest in both non-invasive and at-home solutions, while manufacturing ecosystems support local device innovation and competitive pricing. These regional distinctions necessitate tailored product positioning, regulatory strategy, and channel partnerships. Cross-border expansion should therefore be staged with attention to local reimbursement nuances, training and certification expectations, and culturally informed marketing that resonates with male consumers in each region.
Key corporate strategies and competitive positioning insights highlighting how evidence, clinician education, and partnership models determine market leadership
Competitive dynamics are being reshaped by firms that combine clinical credibility with scalable commercial models, and the vendor landscape now includes specialized device manufacturers, legacy surgical brands, and nimble entrants focused on at-home modalities. Leading companies are differentiating through evidence generation, clinician education programs, and integrated service models that reduce friction for adoption. In particular, those that invest in robust clinical training and clear outcome measurement frameworks earn faster clinician trust and wider referral corridors.
At the same time, strategic partnerships between technology providers and provider networks are emerging as a preferred route to scale, enabling manufacturers to bundle hardware, consumables, and training into predictable deployment packages. Distribution partners and franchised chains that can standardize protocols and deliver consistent patient experiences gain an advantage in consumer-facing markets. Overall, market leaders will be those that align product development with clinician workflows, substantiate claims through real-world data, and create repeatable commercial models that lower the cost and complexity of adoption for provider partners.
Actionable and prioritized recommendations for executives to align product development, supply-chain resilience, and channel strategies to capture male aesthetics demand
Industry leaders should prioritize a three-part agenda that aligns product, channel, and clinical adoption to capture emergent demand and protect margins. First, accelerate investments in clinician-facing education and outcome tracking to shorten the adoption curve for higher-efficacy modalities and to justify premium pricing. These efforts should be coupled with clear protocols that reduce variability in results and create reproducible case studies for payers and referrers.
Second, diversify supply-chain footprints and pursue nearshoring or multi-sourcing where feasible to mitigate tariff exposure and improve lead-time resilience. Operationally, this also includes redesigning procurement contracts to provide flexibility in component sourcing and to lock in service-level guarantees. Third, tailor go-to-market approaches by aligning provider type strategies with treatment frequency and outcome duration profiles; for example, emphasize series-based protocols and semi-permanent outcomes in clinic channels that excel at patient retention, while promoting at-home devices and topical systems in high-frequency, convenience-driven environments. Implementing these recommendations will require cross-functional coordination among R&D, commercial, and operations teams to translate strategic intent into measurable execution.
Transparent mixed-method research methodology combining clinician interviews, device technology review, supplier validation, and scenario mapping to inform practical strategic insights
The research underpinning this analysis combined qualitative interviews with clinicians, technology executives, and provider operators alongside systematic review of regulatory filings, clinical trial registries, and publicly available product literature to triangulate trend signals. Primary engagement included structured conversations with practitioners across dermatology clinics, medical spas, franchised chains, and grooming-adjacent operators to understand clinical pathways, training requirements, and patient acceptance criteria. Secondary analysis synthesized device technology roadmaps across laser, radiofrequency, and ultrasound modalities to identify patterns in capital intensity and clinical workflow integration.
Data integrity was supported by cross-validation of supplier and distributor interviews to assess procurement dynamics and lead-time variability, and by scenario mapping to evaluate the operational impact of tariff changes. Throughout, emphasis was placed on evidence quality, reproducibility of clinical outcomes, and the practical implications for provider adoption and commercial deployment. This mixed-method approach ensured that insights are actionable and grounded in both practitioner experience and documented device performance.
Concise concluding synthesis that connects clinical credibility, operational resilience, and regional strategy into a cohesive roadmap for sustained leadership in male aesthetics
In conclusion, male aesthetics is entering a period of sustained structural change driven by shifting consumer norms, modality convergence, and supply-chain realignment. These forces create both opportunities and challenges for companies seeking to scale responsibly while maintaining clinical credibility and financial discipline. The convergence of minimally invasive and non-invasive modalities, coupled with diversified provider channels, requires an integrated approach that aligns clinical evidence, training, and repeatable patient journeys.
Moving forward, organizations that proactively address procurement resilience, invest in outcome-driven clinician engagement, and tailor regional strategies will be best positioned to capture durable value. The insights in this report are intended to inform both near-term operational decisions and longer-term portfolio planning, enabling leaders to convert trend awareness into competitive advantage without sacrificing clinical standards or patient trust.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increased adoption of noninvasive hair restoration technologies using low-level laser therapy and platelet-rich plasma for androgenic alopecia
- 5.2. 3D imaging and body composition analytics enhance male treatment planning and outcome tracking for contouring and skin tightening
- 5.3. Surge in male grooming products infused with CBD and adaptogens targeting stress reduction and skin rejuvenation
- 5.4. Expansion of cosmetic injectables with innovative neuromodulators and long-lasting dermal fillers for masculine facial structure
- 5.5. Rising popularity of personalized dermatological treatments for men based on genetic and microbiome profiling to optimize skin health
- 5.6. Growing preference for at-home aesthetic devices offering ultrasound and microcurrent therapies to address signs of aging and muscle toning in men
- 5.7. Integration of teledermatology platforms with AI-driven skin analysis tools to deliver tailored skincare recommendations for male consumers remotely
- 5.8. Shift towards sustainable and gender-inclusive skincare packaging and formulations appealing to eco-conscious male shoppers
- 5.9. Laser beard shaping and neck hair removal grow as men seek ingrown-hair relief and clean jawlines with long-lasting results
- 5.10. Stacked energy treatments combining RF microneedling and fractional lasers gain traction for acne scarring in diverse male skin types
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Male Aesthetics Market, by Treatment Type
- 8.1. Minimally Invasive Procedures
- 8.1.1. Fat Transfer
- 8.1.2. Laser-Assisted Lipolysis
- 8.1.3. Liposuction
- 8.1.4. Thread Lifts
- 8.2. Non-Invasive Procedures
- 8.2.1. Body Contouring
- 8.2.2. Botox Injectables
- 8.2.3. Hair Removal
- 8.2.4. Hair Restoration (Non-Surgical)
- 8.2.5. Pigment/Scar Correction
- 8.2.6. Skin Resurfacing
- 8.2.7. Skin Tightening
- 8.3. Surgical Procedures
- 8.3.1. Body Surgery
- 8.3.2. Facial Surgery
- 8.3.3. Hair Transplant
- 8.4. Topicals & At-Home
- 8.4.1. At-Home Devices
- 8.4.2. Skincare
- 9. Male Aesthetics Market, by Technology
- 9.1. Laser Technology
- 9.2. Radiofrequency
- 9.3. Ultrasound
- 10. Male Aesthetics Market, by Provider Type
- 10.1. Barbershop-Adjacent Grooming Clinics
- 10.2. Dermatology Clinics
- 10.3. Franchised Chains
- 10.4. Medical Spas
- 11. Male Aesthetics Market, by Treatment Frequency
- 11.1. Maintenance/Booster
- 11.2. One-Time
- 11.3. Series-Based
- 12. Male Aesthetics Market, by Outcome Duration
- 12.1. Long-Lasting (>24 Months)
- 12.2. Permanent
- 12.3. Semi-Permanent (6–24 Months)
- 12.4. Temporary (<=6 Months)
- 13. Male Aesthetics Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Male Aesthetics Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Male Aesthetics Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Stryker Corporation
- 16.3.2. Zimmer Biomet Holdings, Inc.
- 16.3.3. Solta Medical by Bausch Health Companies Inc.
- 16.3.4. Abbvie Inc.
- 16.3.5. Acumed, LLC by Colson Medical, LLC
- 16.3.6. Alma Lasers, Ltd.
- 16.3.7. Anthony Skin LLC
- 16.3.8. Candela Corporation
- 16.3.9. Cartessa Aesthetics
- 16.3.10. Cutera, Inc.
- 16.3.11. Cynosure, LLC
- 16.3.12. Galderma SA
- 16.3.13. Hanson Medical, Inc.
- 16.3.14. Implantech Associates Inc.
- 16.3.15. Inmode Ltd
- 16.3.16. Institut Straumann AG
- 16.3.17. Integra LifeSciences Corporation
- 16.3.18. Ipsen Pharma
- 16.3.19. Jeisys Medical Inc.
- 16.3.20. Johnson & Johnson Services Inc.
- 16.3.21. KLS Martin Group
- 16.3.22. Lattice Medical SAS
- 16.3.23. Medytox, Inc.
- 16.3.24. Merz Aesthetics, Inc.
- 16.3.25. Nobel Biocare Services AG
- 16.3.26. Quanta System S.p.A.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
